The Chain: Protein Engineering Podcast
The Chain explores the lives, careers, research, and discoveries of protein engineers and scientists, the impact their work is having on the field, and where the industry is headed. Tune in to stay up-to-date on the newest advancements and to hear the stories that are impacting the world of biologics.
- Update frequency
- every 20 days
- Average duration
- 29 minutes
- Episodes
- 80
- Years Active
- 2019 - 2025
Episode: 57 - The Future of Bispecific Antibody Drug Conjugates With Rakesh Dixit, Ph. D.
Bispecific antibody drug conjugates (ADCs) have been undergoing a renaissance in recent years. As big pharma continues to express more interest, what can the field expect for the future of ADCs? In t…
Episode: 56 - Thomas Sakmar on the Golden Age for the Application of Biologics to GPCR Pharmacology
What can we expect from GPCRs in antibodies and biologics? In this episode of The Chain, host Rajesh Sundaresan, PhD, Scientific Leader and GSK Fellow of Protein Cell and Structural Sciences at Glaxo…
Episode: 55 - Tala Fakhouri Discusses AI/ML for Biologics Drug Discovery & Development
In this episode of The Chain, Richard Bonneau, PhD, and Marcel Hop, PhD, of Genentech interview Tala Fakhouri, PhD, of the FDA on her thoughts on the discussion paper, “Using Artificial Intelligence …
Episode: 54 - Enkelejda Miho on the Current State of AI: Drug Development, Research, and the Future
With the whirlwind development of AI, it can be difficult to keep track of its uses in both research and the market. In this episode of The Chain podcast, host Ben Hackel, Professor of Chemical Engin…
Episode: 53 - Jonathan Sockolosky on Breaking Into Biotech and Making Real Progress in Ovarian Cancer Treatments
What is the first step of getting into biotech? How do you make real progress in research? In honor of Ovarian Cancer Awareness Month, host Nimish Gera discusses these topics and more with Jonathan S…
Episode 52: Entrepreneurship in Immunotherapy: Capstan’s Adrian Bot on Teambuilding
In this episode of The Chain, Brandon Dekosky, Associate Professor at MIT, speaks with Adrian Bot, Founding Chief Scientific Officer and Executive Vice President of R&D at Capstan Therapeutics, about…
Episode: 51 - Setting the Right Strategy to Drive Engineering Parameters for Solid Tumor-Targeting T Cell-Engagers
In this special episode of The Chain, G. Jonah Rainey, Senior Director of Protein Engineering at Eli Lilly and Company, hosts a panel at PEGS 2023 to discuss strategies to engineer parameters for sol…
Episode: 50 - Pivoting Research with Antibody Drug Conjugates
In this month’s episode of The Chain, Greg M. Thurber, associate professor of chemical engineering and biomedical engineering at the University of Michigan, sits with moderator Nimish Gera, vice pres…
Episode: 49 - Building a Next Generation Bioproduction Platform
Kyron.Bio is revolutionizing drug production with its Next Generation Bioproduction Platform that will make the production of therapeutics easier, cheaper and faster. Voldborg and McLaughlin talk abo…
Episode: 48 - A Conversation with Peter Tessier: Classifying Antibodies to Assess Biologics Developability Features Early in the Discovery Process
In this month’s episode of the Chain, guest Peter Tessier, Albert M. Mattocks pharmaceutical sciences and chemical engineering professor at the University of Michigan, speaks with moderator Tariq Gha…
Episode: 47 - Bonus Episode with PEGS Young Scientist Keynote Dr. Andrew Anzalone on Engineering Prime Editor Proteins for Therapeutic Applications
Dr. Andrew Anzalone, head of the Prime Editing Platform and scientific co-founder at Prime Medicine, is the winner of the PEGS Boston 2023 Young Scientist Keynote. He was invited to sit down with Bra…
Episode: 46 - Leveraging Albumin and IgG FcRn-Mediated Regulation in Therapeutic Development
Jan Terje Andersen, professor of biomedical innovation in the Department of Pharmacology at the University of Oslo and research group leader in the Department of Immunology at the Oslo University Hos…
Episode: 45 - Advances in Targeted Protein Degradation
In this month’s episode of the Chain, Jim Wells, professor of pharmaceutical chemistry and cellular and molecular pharmacology at the University of California, San Francisco, sits down with moderator…
Episode 44: Structure Forward: Using Structural Biology Pipelines to Achieve Favorable Antibody Responses
Over the last two decades, cryogenic electron microscopy (cryo-EM) has transformed from what Dr. Andrew Ward calls the “outcast of structural biology” to one of the most promising technologies in the…
Episode: 43 - Evolution of Antibody Technologies
Dame Jane Osbourn, chief scientific officer at Alchemab Therapeutics, speaks with Ahuva Nissim, antibody and therapeutic engineering professor at Queen Mary University of London William Harvey Resear…
Episode: 42 - Machine Learning Informatics for Antibody Discovery
Charlotte Deane, professor of structural bioinformatics at the University of Oxford and upcoming speaker at the 14th Annual PEGS Europe Conference in Barcelona, joins moderator Brandon DeKosky, assis…
Episode: 41 - Introduction and Evolution of the Antibody Patent Landscape
After over 25 years as an intellectual property (IP) attorney, Jane Remillard, Nelson Mullins patents and biotechnology IP senior partner, is well-versed in navigating drug development and antibody p…
Episode 40: Exploring Developability Concepts with Bispecific Antibodies
Dr. Nimish Gera, Head of Biologics at Mythic Therapeutics, sits down with Christina Lingham, Executive Director of Conferences and Fellow at Cambridge Healthtech Institute, in this Episode of the Cha…
Episode 39: René Hoet on Antibody Discovery and Following Your Heart
Rene Hoet is working for over 20 years in Biotech and Pharma Industry focusing on Antibody Research and development.
Since April 1 2021 Rene works as Chief Scientific Officer at Montis Biosciences, Le…
Episode 38: Pivoting to Meet Protein Purification Needs with TriAltus
A University of Alabama Birmingham researcher was frustrated with inconsistent solutions and processes for purifying unique proteins and set out to develop a new approach for high throughput protein …